Meeting
2020 ASCO Virtual Scientific Program
Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.
Authors
Tanmayi Pai
Mayo Clinic Florida, Jacksonville, FL
Tanmayi Pai , Angelica Gil , Yaohua Ma , Zhuo Li , Pooja Advani , Alvaro Moreno-Aspitia , Gerardo Colon-Otero , Edith A. Perez , E Aubrey Thompson , Saranya Chumsri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00005970
Citation
J Clin Oncol 38: 2020 (suppl; abstr 529)
DOI
10.1200/JCO.2020.38.15_suppl.529
Abstract #
529
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
First Author: Hans-Christian Kolberg
Poster
2021 ASCO Annual Meeting
Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database.
First Author: Vidya Kollu
Poster
2019 ASCO Annual Meeting
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
First Author: Theodoros Foukakis
